Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 17 unusual trades. Delving into the details, we found 52% of ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

Jim Cramer recently talked about the market selloff and how years of profits are lost within days when panic hits the market: ...

Eli Lilly and Company's VERZENIO (abemaciclib) Overview VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

In the fourth quarter, the company's cancer drug, Verzenio, reported sales of $1.6 billion, up 36% year over year. Eli Lilly's immunosuppressant Taltz racked up revenue of $952 million ...